ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Correlation analysis of Serum Amyloid A, Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Systemic Immune-Inflammation Index with neoadjuvant Therapy Efficacy and Prognosis in Breast Cancer
Provisionally accepted
- 1Guangxi Medical University Cancer Hospital, Nanning, China
- 2Guangxi key Laboratory for Genomic and Personalized Medicine, Nanning, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Previous studies have extensively explored the relationships between the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) with treatment efficacy and prognosis in breast cancer, though the conclusions have been inconsistent. Currently, research on serum amyloid A (SAA) in this context remains limited. This study aims to comprehensively evaluate the association of SAA, NLR, PLR, and SII with treatment response and prognosis in breast cancer, in order to explore which inflammatory marker may have the greatest prognosis value. Patients and Methods: We retrospectively analyzed 348 breast cancer patients treated between 2019 and 2021, including 113 patients who received neoadjuvant chemotherapy. Patients were stratified based on levels of inflammatory markers (SAA: 2.06 mg/L; NLR: 2.50; PLR: 162.89; SII: 650.66). The outcomes assessed included pathological complete response (pCR) and objective response rate (ORR) to neoadjuvant therapy, event-free survival (EFS), and overall survival (OS). Statistical analyses were conducted using Log-rank tests, Cox regression, and Logistic regression. Results: Multivariate analysis identified high SAA as an independent correlate of reduced ORR (OR = 0.26, 95%CI: 0.08-0.80, p = 0.021). No inflammatory markers were found to have statistically significant correlates for pCR. For long-term prognosis, both elevated SAA and SII were independently associated with shorter OS (SAA: HR = 2.67, 95%CI: 1.14-6.26, p = 0.024; SII: HR = 2.65, 95%CI: 1.11-6.32, p = 0.028). Subgroup analysis revealed that among HER2+ patients, high SAA was independently correlated with both worse EFS (HR = 2.53, 95%CI: 1.06-6.07, p = 0.037) and OS (HR = 4.68, 95%CI: 1.11-19.70, p = 0.035). While, the independent associations of NLR and PLR with clinical outcomes were lost after adjusting for clinical confounders. Conclusion: SAA appears to be independently associated with both ORR to neoadjuvant therapy and long-term survival outcomes in breast cancer patients, particularly those with HER2+ status, when compared to NLR, PLR, and SII.
Keywords: breast cancer, Inflammatory biomarkers, Neoadjuvant Therapy, prognosis, serum amyloid A
Received: 29 Aug 2025; Accepted: 16 Feb 2026.
Copyright: © 2026 Nong, Zhou, Deng, Liu, Liang, Jiang, Ye and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Aihua Tan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.